OTCPK:BIESF (Germany)
Â
Vorz-Inhaber-Akt ohne Stimmrecht
$
30.48
0 (0%)
10:08 PM EST
Business Description
Biotest AG
NAICS : 325412
ISIN : DE0005227235
Share Class Description:
BIESF: Vorz-Inhaber-Akt ohne StimmrechtCompare
Compare
Traded in other countries / regions
0N70.UKBIO3.GermanyBIO3.AustriaBIO3.SwitzerlandBIESF.USA IPO Date
2014-01-09Description
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | 0.37 | |||||
| Debt-to-Equity | 1.16 | |||||
| Debt-to-EBITDA | 2.62 | |||||
| Interest Coverage | 5.31 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.58 | |||||
| Beneish M-Score | -1.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.2 | |||||
| 3-Year EBITDA Growth Rate | 135.8 | |||||
| 3-Year FCF Growth Rate | 6.2 | |||||
| 3-Year Book Growth Rate | 4.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -11.91 | |||||
| 12-1 Month Momentum % | -26.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.04 | |||||
| Quick Ratio | 0.91 | |||||
| Cash Ratio | 0.25 | |||||
| Days Inventory | 317.84 | |||||
| Days Sales Outstanding | 74.43 | |||||
| Days Payable | 51.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.14 | |||||
| Forward Dividend Yield % | 0.14 | |||||
| 5-Year Yield-on-Cost % | 0.14 | |||||
| Shareholder Yield % | -2.92 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.14 | |||||
| Operating Margin % | 25.87 | |||||
| Net Margin % | 25.26 | |||||
| FCF Margin % | 2.88 | |||||
| ROE % | 46.28 | |||||
| ROA % | 15.48 | |||||
| ROIC % | 18.91 | |||||
| ROC (Joel Greenblatt) % | 24.81 | |||||
| ROCE % | 21.53 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 8.03 | |||||
| PE Ratio without NRI | 8.03 | |||||
| Shiller PE Ratio | 165.97 | |||||
| PS Ratio | 2.03 | |||||
| PB Ratio | 3.1 | |||||
| Price-to-Tangible-Book | 3.19 | |||||
| Price-to-Free-Cash-Flow | 68.77 | |||||
| Price-to-Operating-Cash-Flow | 68.77 | |||||
| EV-to-EBIT | 7.95 | |||||
| EV-to-Forward-EBIT | -67.78 | |||||
| EV-to-EBITDA | 7.95 | |||||
| EV-to-Forward-EBITDA | 210.88 | |||||
| EV-to-Revenue | 2.3 | |||||
| EV-to-Forward-Revenue | 3.34 | |||||
| EV-to-FCF | 80.91 | |||||
| Price-to-Projected-FCF | 8.72 | |||||
| Price-to-Median-PS-Value | 0.86 | |||||
| Price-to-Graham-Number | 1.06 | |||||
| Earnings Yield (Greenblatt) % | 12.58 | |||||
| FCF Yield % | 1.68 | |||||
| Forward Rate of Return (Yacktman) % | -1.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BIESF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biotest AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 875.872 | ||
| EPS (TTM) ($) | 5.549 | ||
| Beta | 0.12 | ||
| Volatility % | 19.47 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.009492 | ||
| 20-Day SMA ($) | 30.48 | ||
| 12-1 Month Momentum % | -26.47 | ||
| 52-Week Range ($) | 28.78 - 41.45 | ||
| Shares Outstanding (Mil) | 39.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biotest AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biotest AG Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biotest AG Frequently Asked Questions
What is Biotest AG(BIESF)'s stock price today?
The current price of BIESF is $30.48. The 52 week high of BIESF is $41.45 and 52 week low is $28.78.
When is next earnings date of Biotest AG(BIESF)?
The next earnings date of Biotest AG(BIESF) is .
Does Biotest AG(BIESF) pay dividends? If so, how much?
The Dividend Yield %  of Biotest AG(BIESF) is 0.14% (As of Today), Highest Dividend Payout Ratio of Biotest AG(BIESF) was 0.4. The lowest was 0.01. And the median was 0.24. The  Forward Dividend Yield % of Biotest AG(BIESF) is 0.14%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers